Zoetis today announced that the company is accepting grant proposals for research into innovative approaches to help protect dogs, cattle, sheep and poultry from parasitic diseases and to extend the efficacy of therapeutics through new formulations. Through a grant awards program, Zoetis will award a minimum of $25,000 and maximum of $150,000 to support each selected grant proposal. More than one grant may be awarded.
“We at Zoetis are interested in advancing novel approaches to protect animals from parasitic diseases, to improve the health and productivity of livestock animals and to help companion animals live longer, healthier lives,” said Debra Woods, PhD, research director, Head of Parasitology Global Therapeutics Research, Zoetis. “Through this grant program, we aim to energize investigation into anti-parasitic therapeutics research and advance science in this area of high need in animal health.”
Zoetis is seeking proposals focused on helping to protect dogs from heartworm disease by taking novel biological or biopharmaceutical approaches to prevention and on developing diagnostic tools to detect the early stages of infection. Projects might also look at understanding early stages of heartworm infection, including the mechanisms of their migration through the tissues to the heart.
In cattle and sheep, Zoetis is seeking proposals that explore approaches to protect cattle and sheep from endoparasites, in particular to control resistant nematodes and trematodes and to prevent cryptosporidiosis.
Proposals in poultry should look at new approaches to control coccidiosis.
Zoetis is also seeking proposals that could extendthe duration of efficacy of active ingredients using persistent formulations.
To apply, download and complete the application form at www.zoetis.com/innovation/research-development and follow the instruction for submission. The application deadline is Feb. 28, 2018. Grant applications will be reviewed by a Zoetis committee composed of leaders from across divisions and disciplines. Candidates will be notified of the committee’s decision by March 31, 2018.
Zoetis is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 60 years of experience in animal health, Zoetis discovers, develops, manufactures and markets veterinary vaccines and medicines, complemented by diagnostic products, genetic tests, biodevices and a range of services. Zoetis serves veterinarians, livestock producers and people who raise and care for farm and companion animals with sales of its products in more than 100 countries. In 2016, the company generated annual revenue of $4.9 billion with approximately 9,000 employees. For more information, visit www.zoetis.com.